These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23116058)

  • 21. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
    Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
    [No Abstract]   [Full Text] [Related]  

  • 22. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.
    Branford S; Yeung DT; Prime JA; Choi SY; Bang JH; Park JE; Kim DW; Ross DM; Hughes TP
    Blood; 2012 May; 119(18):4264-71. PubMed ID: 22431575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.
    Bozkurt S; Özkan T; Özmen F; Baran Y; Sunguroğlu A; Kansu E
    Hematology; 2013 Jul; 18(4):217-23. PubMed ID: 23394612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.
    Nieborowska-Skorska M; Flis S; Skorski T
    Leukemia; 2014 Dec; 28(12):2416-8. PubMed ID: 25151958
    [No Abstract]   [Full Text] [Related]  

  • 27. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Part II: management of resistance to imatinib in chronic myeloid leukaemia.
    Apperley JF
    Lancet Oncol; 2007 Dec; 8(12):1116-1128. PubMed ID: 18054881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
    Marin D
    J Clin Oncol; 2014 Feb; 32(5):379-84. PubMed ID: 24419129
    [No Abstract]   [Full Text] [Related]  

  • 31. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
    Moser O; Krumbholz M; Thiede C; Tauer JT; Janz I; Lauten M; Dilloo D; Metzler M; Suttorp M
    Pediatr Blood Cancer; 2014 Nov; 61(11):2080-2. PubMed ID: 24810322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Imatinib therapy in chronic myeloid leukemia].
    Egyed M; Kollár B; Rajnics P; Karádi E; Matolcsi A
    Orv Hetil; 2008 Aug; 149(32):1509-12. PubMed ID: 18672441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?
    Richter J; Söderlund S; Lübking A; Dreimane A; Lotfi K; Markevärn B; Själander A; Saussele S; Olsson-Strömberg U; Stenke L
    J Clin Oncol; 2014 Sep; 32(25):2821-3. PubMed ID: 25071107
    [No Abstract]   [Full Text] [Related]  

  • 35. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
    Langabeer SE; Crampe M; Haslam K; Kelly J; Cahill MR
    Leuk Res; 2010 Jul; 34(7):e176-7. PubMed ID: 20153526
    [No Abstract]   [Full Text] [Related]  

  • 36. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
    Dong Y; Xiong M; Duan L; Liu Z; Niu T; Luo Y; Wu X; Xu C; Lu C
    Apoptosis; 2014 Aug; 19(8):1281-92. PubMed ID: 24830786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
    Okabe S; Tauchi T; Ishii Y; Akahane D; Nunoda K; Honda S; Takaku T; Ohyashiki K
    Int J Hematol; 2007 Feb; 85(2):173-4. PubMed ID: 17321998
    [No Abstract]   [Full Text] [Related]  

  • 38. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. After imatinib: new hopes for chronic myeloid leukaemia.
    Bradbury J
    Drug Discov Today; 2005 Apr; 10(8):536-7. PubMed ID: 15837592
    [No Abstract]   [Full Text] [Related]  

  • 40. Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.
    Xiao Y; Hu HH; Wang HX; Zhu XJ; Zou P; Chen ZC; Zhong ZD; Li WM; You Y
    Acta Pharmacol Sin; 2012 Jul; 33(7):979-80. PubMed ID: 22684027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.